Lucy Langer, MD
Hematology & Oncology · Portland, ORNPI 1689705402
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 28.0% of the total. Reporting peaked in 2021 at $6,515 and has fallen 92.9% since, to $465 in 2025.
Across 42 payments — averaging $436.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$5K
- Pfizer$5K
- Illumina, Inc.$3K
- AbbVie$2K
- AstraZeneca$1K
- Puma Biotechnology, Inc.$1K
- plus $2K from 5 others
Across 2 payments — averaging $18,747 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$37K
What the payments were for
- Consulting fees$8,68547%
- Speaking & faculty fees$4,35024%
- Travel & lodging$2,02511%
- Food & beverage$2,65014%
- Education$410%
- Gifts$5813%
- Entertainment$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 9 | $5,128 |
| Pfizer | 4 | $4,913 |
| Illumina, Inc. | 9 | $2,618 |
| AbbVie | 3 | $1,797 |
| AstraZeneca(2 entities) | 4 | $1,352 |
| Puma Biotechnology, Inc. | 1 | $1,000 |
| Genentech USA, Inc. | 2 | $864 |
| Daiichi Sankyo Inc. | 4 | $353 |
| Gilead(2 entities) | 3 | $157 |
| Foundation Medicine, Inc. | 1 | $136 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$5,109
- NovaSeq 6000Dx Sequencer Instrument$2,364
- Venclexta$1,797
- LYNPARZA$1,110
- Nerlynx$1,000
- IBRANCE$788
- Enhertu$236
- SOLIRIS$150
- FOUNDATIONONE CDX$136
- Oncology Testing$109
How this compares
$18,345 in reported general payments places this provider in the 85th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Portland
- Brian DrukerPortland$1.9M
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
- Miklos SimonPortland$13K
- Alexandra SokolovaPortland$12K
- Jacqueline VukyPortland$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.